Result of AGM & Board change

Bioventix plc                                 

                        ("Bioventix" or the "Company")                         

                         Result of AGM & Board change                          

Bioventix plc (ISDX: BVXP) announces that at its Annual General Meeting held
yesterday resolutions 1, 2, 3, 5, 6 and 7 were duly passed.

Resolution 4, in respect of Kim Tan's re-election as a Non-Executive Director,
was not put to shareholders.

Accordingly, Mr. Tan has left the Board with immediate effect.

For further information please contact:

Bioventix plc            Chief Executive Officer   Tel: [phone]      
                                                                           
Peter Harrison                                                             
                                                                           
finnCap Ltd              Corporate Finance         Tel: [phone]      
                                                                           
Geoff Nash/Simon Hicks   Corporate Broking                                 
                                                                           
Tom Jenkins                                                                

About Bioventix plc:

Bioventix (www.bioventix.com) specialises in the development and commercial
supply of high-affinity monoclonal antibodies with a primary focus on their
application in clinical diagnostics, such as in automated immunoassays used in
blood testing. The antibodies created at Bioventix are generated in sheep and
are of particular benefit where the target is present at low concentration and
where conventional monoclonal or polyclonal antibodies have failed to produce a
suitable reagent. Bioventix currently offers a portfolio of antibodies to
customers for both commercial use and R&D purposes, for the diagnosis or
monitoring of a broad range of conditions, including heart disease, cancer,
fertility, thyroid function and drug abuse. Bioventix currently supplies
antibody products and services to the majority of multinational clinical
diagnostics companies. Bioventix is based in Farnham, UK and its shares (BVXP)
were admitted to trading on PLUS-SX in April 2010.